Evaluation and Management of Hepatocellular Carcinoma
Evaluation and Management of Hepatocellular Carcinoma
复制标题
DOI：
10.1016/j.cld.2014.09.002
复制
发表时间：
2015-02-01
影响因子：
5.1
通讯作者：
Chokechanachaisakul, Attasit
中科院分区：
文献类型：
--
作者：
Kulik, Laura M.;Chokechanachaisakul, Attasit
肝细胞癌的负担正在上升，预计将升级，而长期治愈的最佳机会仍然是移植，但可用器官的短缺仍然是一个限制。肝脏定向治疗可以起到移植的桥梁/降级或姑息治疗的作用。尽管HOC患者的总生存率有所改善，但由于手术技术、肝脏定向和全身治疗的进步，5年总生存率仍然较低，为18%，这大大减轻了对新疗法的需求。对HOC的监测是在早期发现疾病的关键，以增加潜在治疗选择的机会。
The burden of hepatocellular carcinoma is rising and anticipated to escalate and while the best chance for long term cure remains transplantation, however the shortage of available organs remains a limitation. Liver directed therapy can serve the role of bridge/downstaging to transplant or as palliative care. Despite an improved overall survival among patients with HOC, due to advancements in surgical techniques, liver directed and systemic therapy, the 5 year overall survival remains low at 18% high-lightening the need for novel therapies. Surveillance for HOC is key to detect disease at an early stage to increase the chances for a potentially curative option.